BidaskClub lowered shares of Corcept Therapeutics (NASDAQ:CORT) from a buy rating to a hold rating in a research report sent to investors on Wednesday morning.

CORT has been the subject of several other research reports. Stifel Nicolaus initiated coverage on shares of Corcept Therapeutics in a research report on Thursday, August 31st. They set a buy rating and a $20.00 price target for the company. Zacks Investment Research downgraded shares of Corcept Therapeutics from a buy rating to a hold rating in a research report on Tuesday, October 10th. Finally, Piper Jaffray Companies set a $18.00 price target on shares of Corcept Therapeutics and gave the company a buy rating in a research report on Thursday, August 24th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock presently has an average rating of Buy and a consensus price target of $21.00.

Shares of Corcept Therapeutics (CORT) traded up $0.03 on Wednesday, hitting $15.80. 1,366,000 shares of the company traded hands, compared to its average volume of 1,120,383. The company has a market capitalization of $1,799.74, a P/E ratio of 54.38 and a beta of 1.89. Corcept Therapeutics has a 12 month low of $6.70 and a 12 month high of $20.77.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported $0.11 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.13 by ($0.02). The firm had revenue of $42.70 million for the quarter, compared to the consensus estimate of $41.64 million. Corcept Therapeutics had a net margin of 27.28% and a return on equity of 58.17%. Corcept Therapeutics’s revenue was up 96.8% on a year-over-year basis. During the same period last year, the business earned $0.02 EPS. equities research analysts anticipate that Corcept Therapeutics will post 0.47 EPS for the current year.

In related news, Director G Leonard Baker, Jr. sold 30,000 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $17.59, for a total value of $527,700.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Robert S. Fishman sold 8,000 shares of the firm’s stock in a transaction that occurred on Friday, December 8th. The stock was sold at an average price of $16.72, for a total transaction of $133,760.00. Following the completion of the sale, the insider now owns 8,000 shares in the company, valued at approximately $133,760. The disclosure for this sale can be found here. Company insiders own 19.20% of the company’s stock.

A number of hedge funds have recently modified their holdings of the stock. Victory Capital Management Inc. purchased a new position in shares of Corcept Therapeutics during the 3rd quarter worth $108,000. BNP Paribas Arbitrage SA boosted its stake in shares of Corcept Therapeutics by 2,942.9% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 9,707 shares of the biotechnology company’s stock worth $115,000 after acquiring an additional 9,388 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in shares of Corcept Therapeutics by 52.6% during the 2nd quarter. PNC Financial Services Group Inc. now owns 9,837 shares of the biotechnology company’s stock worth $116,000 after acquiring an additional 3,390 shares during the last quarter. Sand Hill Global Advisors LLC purchased a new position in shares of Corcept Therapeutics during the 2nd quarter worth $118,000. Finally, Jasper Ridge Partners L.P. purchased a new position in shares of Corcept Therapeutics during the 2nd quarter worth $118,000. Institutional investors own 64.64% of the company’s stock.

WARNING: This story was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.watchlistnews.com/corcept-therapeutics-cort-lowered-to-hold-at-bidaskclub/1776275.html.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).

Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.